INTRODUCTION
This Amendment No. 1 to Rule 13E-3 Transaction Statement on Schedule 13E-3, together with the exhibits hereto (this “Schedule 13E-3” or “Transaction Statement”), is being filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), jointly by the following persons (each, a “Filing Person,” and collectively, the “Filing Persons”): (i) Gelesis Holdings, Inc. (the “Company”), a Delaware corporation and the issuer of the common stock, par value $0.0001 per share (“Company Common Stock”), that is subject to the Rule 13e-3 transaction, (ii) PureTech Health LLC, a Delaware limited liability company (“Parent”), (iii) PureTech Health plc, a company incorporated under the laws of England and Wales (“PureTech”), and (iv) Caviar Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of parent (“Merger Sub”).
On June 12, 2023, the Company, Parent and Merger Sub entered into an Agreement and Plan of Merger (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions and on the terms set forth therein, the Company will merge with and into Merger Sub, with Merger Sub as the surviving company and a wholly owned subsidiary of Parent (the “Merger”). Concurrently with the filing of this Schedule 13E-3, the Company is filing with the SEC a revised preliminary Proxy Statement (the “Proxy Statement”) under Regulation 14A of the Exchange Act, relating to a special meeting of the stockholders of the Company (the “Special Meeting”) at which the stockholders of the Company will consider and vote upon a proposal to approve and adopt the Merger Agreement and a proposal to adjourn and postpone the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve and adopt the Merger Agreement. A copy of the preliminary Proxy Statement is attached hereto as Exhibit (a)(2)(i). A copy of the Merger Agreement is attached hereto as Exhibit (d)(i) and is also included as Annex A to the preliminary Proxy Statement and incorporated herein by reference.
Under the terms of the Merger Agreement, if the Merger is completed, each share of Company Common Stock outstanding immediately prior to the consummation of the Merger (other than as provided below, but including shares issued in connection with the deemed exercise of certain warrants to purchase shares of Company Common Stock) will be converted into the right to receive $0.05664 per share in cash (the “Merger Consideration”), without interest and less any applicable withholding taxes. The following shares of Company Common Stock will not be converted into the right to receive the Merger Consideration in connection with the Merger: (i) shares held in the treasury of the Company, (ii) shares owned by Parent or any of its direct or indirect subsidiaries (including Merger Sub) immediately before the effective time of the Merger, (iii) shares of the restricted Company Common Stock issued pursuant to that certain Business Combination Agreement, dated as of July 19, 2021, by and among Gelesis, Inc., Capstar Special Purpose Acquisition Corp. and CPSR Gelesis Merger Sub, Inc. (as amended, restated, supplemented or otherwise modified, the “BCA”), and subject to all of the terms and conditions of the BCA in respect of the “Earn Out Shares”, and (iv) shares held by Company’s stockholders who perfect their statutory rights of appraisal under Section 262 of the General Corporation Law of the State of Delaware (the “DGCL”), a copy of which is attached hereto as Exhibit (f) and is also included as Annex C to the preliminary Proxy Statement and incorporated herein by reference.
At the Effective Time, each outstanding warrant to purchase shares of Company Common Stock issued pursuant to that certain Warrant Agreement, dated July 1, 2020, by and among Capstar Special Purpose Acquisition Corp., a Delaware corporation, Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Gelesis Warrant Agreement”, and each such warrant, a “Gelesis Warrant”) will automatically and without any required action on the part of the holder thereof, cease to represent a warrant exercisable for one share of Company Common Stock and become a warrant exercisable for the Merger Consideration; provided that if a holder of such Gelesis Warrant properly exercises such Gelesis Warrant within thirty (30) days following the public disclosure of the consummation of the Merger, the holder of such Gelesis Warrant will be entitled to the Black-Scholes Warrant Value (as defined in the Gelesis Warrant Agreement) with respect to such Gelesis Warrant, which would have been equal to less than $0.01 per Gelesis Warrant as of the close of trading on June 12, 2023.
1